The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASCO 2024 | Evolution of the treatment landscape for patients with CNS lymphoma
Lakshmi Nayak, MD, Dana-Farber Cancer Institute, Boston, MA, highlights how the treatment landscape for patients with primary central nervous system (CNS) lymphoma has evolved in recent years. Whilst a few decades back, the only options available were chemotherapy and radiation, there are now several new therapies and immunotherapies being investigated, and patients seem to be responding. Dr Nayak hopes this translates into longer survival and better preservation of neurologic function. This interview took place during the 2024 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
